Weight Loss Linked to Shorter ALS Survival
Weight change in ALS provides a quantified prognostic association, while liposarcoma gene-activity patterns nominate molecular research targets. These distinct findings support replication and follow-up, not causal conclusions or validated treatment thresholds.
Evidence
People with amyotrophic lateral sclerosis (ALS) who lost weight during their first six months of observation had poorer survival than those who gained weight. During 36-month follow-up, median survival was 12.2 months with weight loss versus 31.8 months with weight gain. The estimated hazard of death—the death rate among participants still alive—was 4.78 times as high. Its 95% confidence interval ranged from 2.68 to 8.53, indicating uncertainty about the association’s size.
The ALS weight-change study, published September 8, 2026, included 170 people with ALS and 173 controls without neurodegenerative disease at baseline. This prospective observational study combined comparisons with controls and comparisons between ALS weight-change groups, using data collected from March 2016 to October 2024. Agreement among equation-estimated calorie requirements, reported intake and observed weight patterns was only 17.3%–32.1%. No equation performed consistently across weight-change groups.
The liposarcoma gene-activity study, published September 11, 2026, examined liposarcoma, a cancer of fatty tissue. Its discovery dataset included 89 liposarcoma tissues. Comparisons with normal fatty tissue identified 855 genes with differing activity: 334 higher and 521 lower in tumors. Researchers used biological-pathway analysis, protein-interaction networks and laboratory measurements of RNA—the messages produced from genes. Laboratory validation included 13 liposarcoma and 10 normal tissues.
Higher activity of seven genes was associated with poorer overall survival and less time disease-free in a combined sarcoma cohort, rather than a liposarcoma-only survival analysis. CIBERSORT, a computational method that estimates immune-cell proportions from tissue-wide gene activity, also estimated a higher fraction of resting mast cells, a type of immune cell, in liposarcoma than in normal fat.
Analysis
Interpretation: the connection is about evidence strength, not a demonstrated shared biological mechanism. Repeated weight measurements identify a prognostic signal—information associated with future outcomes—in ALS. Gene activity and inferred immune-cell composition identify candidate biology in liposarcoma. The studies do not confirm one another; they address different diseases with different measurements.
The ALS association is more directly quantified in relation to patient outcomes. The liposarcoma findings primarily narrow the list of molecular signals deserving further investigation. Neither establishes that changing the measured pattern improves outcomes.
Limitations
The ALS study was observational and cannot establish that weight loss caused earlier death. Weight-change classification required participants to survive and remain under observation through six months. Its conclusions therefore depend on reaching that landmark and may be affected by selection bias. Convenience recruitment through one clinic also limits generalizability. Several calorie-estimation equations had not been formally validated against measured total energy expenditure in ALS or Australian ALS cohorts; low agreement is not itself a direct measurement of their accuracy.
For liposarcoma, small subtype samples prevented subtype-specific survival analysis. Associations in a pooled sarcoma cohort cannot establish equivalent associations within each liposarcoma subtype. Laboratory validation was small, and immune-cell fractions were inferred rather than directly counted. The reported molecular findings provide no survival-effect sizes or quantified magnitude for the mast-cell difference.
What to watch
An independent ALS cohort could test whether the weight-loss association persists after accounting for disease severity and the six-month selection requirement. Direct measurement of total energy expenditure would also provide a stronger benchmark for calorie equations.
For liposarcoma, confidence would change with replication—or failure to replicate—of the seven-gene survival associations within individual subtypes, with reported effect sizes, alongside direct tissue measurements testing the estimated increase in resting mast-cell proportion.